Adebrelimab  (Synonyms: 阿得贝利单抗; SHR-1316)

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Chimeric; Humanized

Adebrelimab (SHR-1316; 0.06- 1mg/mL; 48 hours) 抑制 SK-BR-3 和 AU565 细胞的增殖、迁移、侵袭^[1]。
Adebrelimab（SHR-1316；0.1-1mg/mL；48 小时）下调 PD-L1、p-PI3K、p-AKT 的表达并上调 FOXO1 的表达^[1]。 SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL 48 hours Promoted cell apoptosis. SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL 24 hours Decreased the migration rate of SK-BR -3 and AU565 cells. SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL 48 hours Downregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Adebrelimab（SHR-1316；200 μg；每周 3 次；持续 21 天）显示出对肿瘤生长的抑制作用^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2247114-85-6

液体

Colorless to light yellow

阿得贝利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022.

  [2]. Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6.  [Content Brief]